· Published by Health Canada · Official notice
This is duplicated text of a letter from EMD Serono, A Division of EMD Inc., Canada. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 29, 2013
Dear Health Care Professional:
Subject: Cetrotide® 3mg (Cetrorelix for Injection): DIN 02247767
Notification: Reconstitution time may exceed 3 minutes for four lots distributed in Canada: Lot P00005H, P00006F, P00006P and P00007D.
EMD Serono, A Division of EMD Inc., Canada in consultation with Health Canada, is advising you that there is a potential for vials in four identified lots of Cetrotide® 3mg product, that were distributed in Canada during the period October 2011 - March 2013, to have a reconstitution time longer than 3 minutes. Cetrotide® is a gonadotropin-releasing hormone antagonist indicated for prevention of premature ovulation in patients undergoing controlled ovarian stimulation.
The reconstitution time should not normally be more than three minutes, but during laboratory re-testing after batch release, in some vials from the identified batches, reconstitution times were found to exceed three minutes. In some cases the reconstitution times were up to eleven minutes.
The investigation is in progress at the product manufacturer in Europe to determine root cause. Note that Cetrotide® is also supplied in a 0.25mg/vial format (DIN 02247766). This 0.25mg/vial format is not affected by the above mentioned notice.
The involved Cetrotide® 3mg lots (Lot P00005H, Lot P00006F, Lot P00006P and Lot P00007D) were imported into Canada in Oct 2011 to Mar 2013 and were released to the market. There is no indication that market action is required for Cetrotide® 3mg product. Disposition is as follows:
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious or unexpected reactions in patients receiving Cetrotide® 3mg product should be reported to EMD Serono or Health Canada.
EMD Serono, A Division of EMD Inc., Canada
2695 North Sheridan Way, Suite 200
Mississauga ON L5K 2N6
Tel: 1 888 737 6668 ´5160
Fax: 905 919 0292
E-mail: drugsafetycanada@merckserono.net
To correct your mailing address or fax number, contact EMD Serono, A Division of EMD Inc., Canada.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Product and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Tel: 1-800-267-9676
Fax: 613-946-5636
Should you have any questions regarding this notification for Cetrotide® 3mg product, please call the EMD Serono Medical Information/Drug Safety Department at 1-888-737-6668 x5160 or our Customer Service department at 1 800 387 9749.
original signed by
Michael Lopez
Manager& Head of Quality Operations
Peter Grosser, Ph.D.
Director, Scientific Affairs